drug
ML-061
Marketedupdated 5mo agoby Meridian Laboratories Inc
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 71 investigational indications.
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying ML-061
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase1A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- phase3A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- phase2RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- phase2A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- phase3A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- phase3A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
- phase3Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 7, 2031
~4.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- May 16, 2036formulationUS 11419842
- May 16, 2036formulationUS 12090134
- May 16, 2036formulationUS 12090135
- Mar 14, 2036formulationUS 10398785
- Mar 14, 2036formulationUS 10398785
- Mar 14, 2036formulationUS 10398785
- Sep 30, 2033formulationUS 8940786
- Sep 30, 2033formulationUS 8940786
- Sep 30, 2033formulationUS 8940786
- Sep 30, 2033formulationUS 9308195
- Sep 30, 2033formulationUS 9308195
- Sep 30, 2033formulationUS 9308195
- Sep 30, 2033method-of-use (U-2562)US 9763880
- Sep 30, 2033method-of-use (U-2559)US 9763880
- Sep 30, 2033method-of-use (U-2560)US 9763880
- Aug 7, 2031formulationUS 108427704.8y
- Aug 7, 2031formulationUS 108427704.8y
- Aug 7, 2031formulationUS 108427704.8y
News(8)
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1d ago
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 1mo ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 1mo ago
- Pfizer punts Seagen ADC, further muddying value of the $43B buyoutThe co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…biospace · 1mo ago
- RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancerThe data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…biospace · 1mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 5mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 5mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that